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in Medline, EMBASE, International Pharmacological Abstracts and the Cochrane 
Collaboration. Two independent reviewers identiﬁed the abstracts, selected the full 
articles, and extracted the data. Odds ratios and weighted means differences were 
calculated. Random effects models were employed in the analyses with RevMan v.5.0 
software. RESULTS: A total of 1253 studies were reviewed and 10 trials were ﬁnally 
selected where parecoxib was assessed in hip, knee and spine surgeries, as well as 
bunionectomy. In 6/10 studies, parecoxib 40 mg showed a higher global treatment 
evaluation against placebo (OR 0.20; 95%CI 0.13–0.31) and improvements in the 
consuming rescue drugs rate (OR 0.18; 95%CI 0.07–0.47), as well as in cumulative 
morphine consumption, and pain intensity (p < 0.001). In three studies, parecoxib 
was as effective as ketorolac, paracetamol, metamizole or morphine. Frequency of AE 
was similar between parecoxib and placebo or other drugs. Parecoxib 20 mg showed 
less postoperative fever than placebo (OR 0.46; 95%CI 0.24–0.89). CONCLUSIONS: 
Parecoxib 40 mg is an effective and safe analgesic option during the ﬁrst hours of the 
postoperative period in orthopedic surgeries.
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
PSY6
IMPACT OF A PRIOR AUTHORIZATION FOR PREGABALIN ON HEALTH 
PLAN DRUG EXPENDITURES
Bazalo G1, Weiss RC2, Joshi AV3
1Managed Solutions, LLC, Conifer, CO, USA, 2Managed Solutions, LLC, Randolph, NJ, USA, 
3Pﬁzer Inc., New York, NY, USA
OBJECTIVES: The purpose of this study was to model the economic impact of a prior 
authorization (PA) requirement for pregabalin from a US health plan perspective. 
METHODS: An Excel-based model was developed to simulate two hypothetical 
scenarios: 1) A health plan in which a PA is placed on pregabalin, and 2) a health 
plan in which there is no PA. In both scenarios, a mix of brand and generic products 
based on secondary prescription data from IMS was assumed dispensed to patients 
who did not receive a pregabalin prescription or who were denied pregabalin in the 
PA process. PA rejection rates were obtained from a PBM database analysis. The 
pregabalin prescribing rate was set to 10.3% in both the PA and no PA scenarios, 
with a denial rate of 50% in the PA scenario. The model incorporated the drug 
wholesale acquisition cost (WAC) or the federal upper limit for generics, cost of PA 
administration (published literature), and copayments, in each scenario for a cohort 
of 1000 patients over a one-year period. Sensitivity analyses were carried out 
with various PA administration costs and product mixes for the pregabalin alternatives. 
RESULTS: The difference in costs between the two scenarios was 0.4% ($886,000 
for the PA scenario vs. $889,000 for the “no PA” scenario). Setting the PA administra-
tion cost to zero, the difference in drug acquisition costs alone was 0.8%. When the 
product alternatives to pregabalin were replaced with gabapentin only, the difference 
in drug acquisition costs alone was 3.4%. CONCLUSIONS: Based on the actual mix 
of products used across pregabalin indications, a PA on pregabalin has a minimal 
impact on total costs to the health plan. The difference in drug acquisition costs was 
less than 1% for a mix of product alternatives based on audited prescription data.
PSY7
ECONOMIC VALUE OF LIDOCAINE PATCH 5% VS. GABAPENTIN OR 
PREGABALIN IN MEDICAID PATIENTS WITH POST HERPETIC 
NEURALGIA
Ivanova JI1, Puenpatom RA2, Kirson NY3, Birnbaum HG3, Wei R3, Kantor E3, Summers K2
1Analysis Group, Inc., New York, NY, USA, 2Endo Pharmaceuticals, Inc., Chadds Ford, PA, 
USA, 3Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: Compare direct health care resource utilization and costs of post 
herpetic neuralgia (PHN) patients initiating lidocaine or gabapentin/pregabalin. 
METHODS: Patients with PHN diagnosis (ICD-9-CM: 053.12, 053.13 or 053.19) or 
herpes zoster diagnosis (ICD-9-CM: 053.0x, 053.10, 053.11, 053.2x, 053.7x-053.9x) 
and at least 30 days PHN-related treatment were identiﬁed from Medicaid claims data 
from Florida, Iowa, Missouri, and New Jersey, 1999–2007. Patients initiated mono-
therapy with lidocaine or gabapentin/pregabalin after PHN diagnosis, had continuous 
eligibility 6 months before (baseline) and 6 months after (study period) the medication 
index date, and were at least 18 years old. Lidocaine patients were matched to patients 
initiating gabapentin/pregabalin on age and propensity to initiate lidocaine based on 
baseline characteristics. Study period direct resource use and costs, calculated as 
reimbursements to providers for medical services and prescription drugs, were com-
pared between the two matched groups using univariate analysis. RESULTS: After 
matching on age and propensity to initiate lidocaine, baseline characteristics (such as 
age, comorbidities, prior resource use and direct costs) were well-balanced between 
the treatment groups. Matched patients were on average 61 years old, 73% were 
women, approximately 24% had a mental disorder diagnosis, and 55% had other 
painful conditions during the baseline period. Among matched lidocaine (n = 306) 
and gabapentin/pregabalin (n = 306) patients, there were no statistically signiﬁcant 
differences in study period treatment with tricyclic antidepressants (16.0% in both 
groups), analgesic medications (86.6% vs. 86.9%), and other PHN-related treatments 
(6.9% vs. 6.2%) such as DREZ lesions, epidural steroids and nerve blocks. No statisti-
cally signiﬁcant differences were found in resource use, average total health care costs 
per patient ($8,740 vs. $8,630, P = 0.880) and PHN-related costs ($1,046 vs. $1,067, 
P = 0.908) between matched lidocaine and gabapentin/pregabalin patients. CONCLU-
SIONS: PHN patients treated with lidocaine cost no more than patients treated with 
gabapentin or pregabalin over the 6-month study period.
PSY8/CM3
PERSISTENCE WITH INFLIXIMAB MAINTENANCE THERAPY 
DECREASES HOSPITALIZATIONS IN PATIENTS WITH  
ULCERATIVE COLITIS
Waters H1, Carter C1, Smith P2, Smith D3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2IMS Health, Watertown, MA, 
USA, 3IMS Health Incorporated, Watertown, MA, USA
OBJECTIVES: To assess maintenance treatment patterns of inﬂiximab (IFX) in ulcer-
ative colitis (UC) and the impact of persistence on UC-related hospitalization. 
METHODS: A retrospective claims analysis using the IMS LifeLinkTM Health Plan 
Claims Database between September 1, 2004 and March 31, 2009 was conducted. 
The index date was deﬁned as the ﬁrst claim for IFX between September 1, 2005 and 
January 1, 2008. Continuous enrollment for 12 months prior and 14 months after 
the index date was required. Patients were required to have ≥2 claims with an ICD-9 
diagnosis code for UC pre-index and be ≥18 years at index. Patients with selected 
other inﬂammatory diseases and those undergoing colectomy within 12 weeks of the 
index date were excluded. Patients with ≥1 infusion following day 56 post index were 
considered to have maintenance therapy. Hospitalizations were compared to the group 
of patients with induction infusions only. Within the maintenance treatment group, 
therapeutic persistence was deﬁned as a medication possession ratio (MPR) of ≥80%; 
this group was compared to those without therapeutic persistence (<80% MPR). 
RESULTS: A total of 420 patients were included in the analyses; mean (SD) age = 
43.9 (14.1) years; 47.9% female; mean (SD) 6.08 (2.49) IFX infusions; 84.3% (n = 
354) continued to maintenance therapy. Maintenance patients incurred fewer UC-
related hospitalizations (0.12 vs. 0.32), associated costs ($3118 vs. $8610) and had 
shorter average lengths of stay (ALOS; 8.9 vs. 11.65 days) than induction-only 
patients. Among maintenance patients, those demonstrating therapeutic persistence (n 
= 202; 57.1%) incurred fewer UC-related hospitalizations (0.03 vs. 0.22) and associ-
ated costs ($423 vs. $6678), and had shorter ALOS (6.67 vs. 9.71 days) than those 
without therapeutic persistence. CONCLUSIONS: Persistent maintenance treatment 
with IFX is associated with fewer UC-related hospitalizations, lower inpatient costs, 
and shorter ALOS among patients with UC. Physicians should monitor patients with 
UC to ensure appropriate IFX maintenance therapy paradigms are followed.
PSY9
THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE: EVIDENCE 
FROM UNITED STATES NATIONAL SURVEY DATA
Loﬂand J1, Naim A1, Rizzo J2, Gunnarsson C3, Chen J4, Waters H1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Stony Brook University, Stony 
Brook, NY, USA, 3S2 Statistical Solutions Inc, Cincinnati, OH, USA, 4College of Staten Island/
CUNY, Staten Island, NY, USA
OBJECTIVES: To quantify individual and national estimates of the direct costs of 
inﬂammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), 
using national survey data. METHODS: This was a retrospective study using 1996–
2006 data from the Medical Expenditure Panel Survey (MEPS). Individuals self-
reported health conditions were mapped to the International Classiﬁcation of Diseases, 
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic codes. Individuals with an 
ICD-9-CM diagnostic code of 555.x (CD) or 556.x (UC) were categorized as having 
IBD. Health care services included prescriptions, inpatient, outpatient, emergency 
room, ofﬁce, and home health services. Health care costs were collected for the health 
care services. Out-of-pocket (OOP) costs were the portion of individuals’ total pay-
ments for the health care services. To estimate the health care and OOP costs, an 
ordinary least squares model was performed. Individuals with and without IBD were 
compared. RESULTS: There were 411 individuals with IBD (mean age = 47.7 years; 
57% Female), and 161,953 individuals without IBD (mean age = 48.2 years; 58% 
Female). The annual per capita health care costs for individuals with IBD were more 
than double those for individuals without IBD ($11,759 vs. $5,700; p < 0.001). The 
annual per capita OOP costs for individuals with IBD were also almost twice those 
of individuals without IBD ($2,082 vs. $1,147; p < 0.001). When combining health 
care and OOP costs, IBD increases the total annual per capita direct costs by $7,021. 
The US national annual estimates of the health care, OOP, and total direct costs 
secondary to IBD are $2.8 billion, $0.4 billion, and $3.2 billion respectively. CON-
CLUSIONS: The direct costs associated with IBD are substantial not only to health 
care payers but to patients as well. The extent to which appropriate and early diagnosis 
and treatment of IBD reduce the total health care costs for individuals with this disease 
should be examined.
PSY10
THE DIRECT MEDICAL COSTS OF PSORIASIS: EVIDENCE FROM UNITED 
STATES NATIONAL SURVEY DATA
Loﬂand J1, Rizzo J2, Gunnarsson C3, Chen J4, Waters H1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Stony Brook University, Stony 
Brook, NY, USA, 3S2 Statistical Solutions Inc, Cincinnati, OH, USA, 4College of Staten Island/
CUNY, Staten Island, NY, USA
OBJECTIVES: To quantify individual and national estimates of the direct medical 
costs of psoriasis (PsO) and similar disorders, using national survey data. METHODS: 
This was a retrospective study using 1996–2006 data from the Medical Expenditure 
Panel Survey (MEPS). Individuals’ self-reported current health conditions were 
mapped to International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation 
(ICD-9-CM) diagnostic codes. Individuals with an ICD-9-CM diagnostic code of 696.
xx were categorized as having PsO. Health care services included prescriptions, inpa-
tient, outpatient, emergency room, ofﬁce, and home health services. Health care costs 
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were collected for the health care services. Out-of-pocket (OOP) costs were the portion 
of individuals’ total payments for the health care services. To estimate the health care 
and OOP costs, a multivariable linear regression analysis was performed. Costs were 
adjusted for patient demographics and comorbidities. All costs were inﬂated using the 
medical component of the 2008 Consumer Price Index (CPI). RESULTS: There were 
873 individuals with PsO (mean age = 51 years; 52% female), and 160,617 individuals 
without PsO, (mean age = 48 years; 58% female). Annual per capita health care costs 
for individuals with PsO were higher than those for individuals without PsO ($4543 
vs. $3828; P = 0.0007). Annual per capita OOP costs for individuals with PsO were 
also higher than those of individuals without PsO ($1250 vs. $917; P < 0.0001). The 
total annual per capita direct medical costs was $5793 when combining health care 
and OOP costs for PsO. The US national annual estimates of health care, OOP, and 
total direct medical costs for PsO were $0.77 billion, $0.36 billion, and $1.1 billion, 
respectively. CONCLUSIONS: The direct medical costs associated with PsO are 
substantial not only to health care payers but to patients as well. The extent to which 
appropriate and early diagnosis and treatment of PsO reduce total health care costs 
for individuals with these diseases should be examined.
PSY11
THE INDIRECT COSTS OF INFLAMMATORY BOWEL DISEASE: 
EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA
Loﬂand J1, Naim A1, Rizzo J2, Gunnarsson C3, Chen J4, Waters H1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Stony Brook University, Stony 
Brook, NY, USA, 3S2 Statistical Solutions Inc, Cincinnati, OH, USA, 4College of Staten Island/
CUNY, Staten Island, NY, USA
OBJECTIVES: To quantify individual and national estimates of the indirect costs of 
inﬂammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), 
using national survey data. METHODS: This was a retrospective study using 1996–
2006 data from the Medical Expenditure Panel Survey (MEPS). Individuals self-
reported health conditions were mapped to the International Classiﬁcation of Diseases, 
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic codes. Individuals with an 
ICD-9-CM diagnostic code of 555.x (CD) or 556.x (UC) were categorized as having 
IBD. A two-part model was speciﬁed to estimate the probability of time lost from 
work and the annual number of workdays missed due to illness, conditional on missing 
at least 1 workday. The annual missed workdays were combined with MEPS earnings 
information to estimate individual and national indirect costs. RESULTS: There were 
200 patients with IBD (mean age = 43.0 years; 54% Female), and 89,846 individuals 
without IBD (mean age = 40.8; 52% Female), included in the analysis. The study 
revealed 71.9% (144/200) of individuals with IBD missed work as compared with 
58.3% (52,110/89,846) of those without IBD (p = 0.0001). Among those individuals 
who missed work, individuals with IBD had a mean annual number of missed work-
days of 13.95 versus 9.83 missed workdays for individuals without IBD (p = 0.004). 
The per capita indirect costs associated with the incremental difference in annual lost 
workdays between those with and without IBD was $485. The estimated national 
indirect costs associated with IBD were $205 million per year. CONCLUSIONS: 
Compared to individuals without IBD, individuals with IBD have a higher probability 
of missing work and missing more workdays. The per capita and national annual 
indirect costs associated with IBD are substantial. The ability of appropriate and early 
diagnosis and treatment of IBD to reduce time lost from work and indirect costs for 
individuals with IBD should be examined.
PSY12
COMPARISON OF ABSENTEEISM AND TOTAL HEALTH CARE 
EXPENDITURES FOR SELECT AUTO-IMMUNE INFLAMMATORY 
DISORDERS (AIID) PRE AND POST ANTI-TNF USE—AN EMPLOYER’S 
PERSPECTIVE
Naim A1, Nair KV2, Bolge S1, Draaghtel K3, Van Den Bos J3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2University of Colorado, 
Aurora, CO, USA, 3Milliman, Inc, Denver, CO, USA
OBJECTIVES: To compare direct and absenteeism-related indirect expenditures 
among employees suffering from an AIID pre and post anti-TNF use. METHODS: A 
retrospective analysis was performed using the Thomson Reuters MarketScan® and 
the Health and Productivity Management databases (2000–2007). Study group con-
sisted of members with primary diagnosis for at least one of six AIIDs (Rheumatoid 
Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing 
Spondylosis) and at least one prescription for an anti-TNF (adalimumab, etanercept, 
or inﬂiximab) in the same calendar year. Direct expenditures included medical expen-
ditures (inpatient, outpatient, emergency department, and other medical services) and 
pharmacy expenditures. Indirect expenditures included expenditures related to absen-
teeism. Regression analysis was used to compare the mean number of annual absentee 
days, indirect expenditures associated with absences, direct expenditures (medical and 
pharmacy), and total expenditures during the 12 months prior versus the 12 months 
following initiation of anti-TNF treatment. RESULTS: The study group (n = 689) was 
39% female with 94% in a managed care plan and had a mean age of 44.3 years. 
Only 22% had more than one AIID condition. Following the use of anti-TNFs, 
absenteeism decreased by 15.4% with lower indirect expenditures ($1172 vs. $1000), 
lower medical expenditures ($7517 vs. $6434), and lower non anti-TNF pharmacy 
expenditures ($1934 vs. $1604). Direct expenditures were higher ($22,658 vs. $9450) 
due to the cost of anti-TNF treatment ($14,620). Consequently, total expenditures 
(direct and indirect) were also higher following anti-TNF use ($23,657 vs. $10,623). 
CONCLUSIONS: AIIDs are debilitating disorders that result in reduced productivity 
and time lost from work. Members with at least one AIID who received anti-TNF 
treatments, had lower absenteeism and indirect health care costs and higher direct 
costs. Appropriate management of these conditions with anti-TNF agents may provide 
greater indirect costs savings which could offset the direct costs.
PSY13
COMPARISON OF TOTAL HEALTH CARE EXPENDITURES AND 
ABSENTEEISM FOR INFLAMMATORY BOWEL DISEASE FROM AN 
EMPLOYER’S PERSPECTIVE
Naim A1, Nair KV2, Van Den Bos J3, Draaghtel K3, Waters H1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2University of Colorado, 
Aurora, CO, USA, 3Milliman, Inc, Denver, CO, USA
OBJECTIVES: To compare direct and absenteeism-related indirect expenditures 
among employees with inﬂammatory bowel disease (IBD) (Crohn’s Disease, Ulcerative 
Colitis) with employees who do not have IBD. METHODS: A retrospective analysis 
was performed using the Thomson Reuters MarketScan® and the Health and Produc-
tivity Management databases between 2000–2006. Propensity analysis adjusting for 
various demographic and clinical variables was used to create 1) control: no diagnosis 
of any IBD; and 2) IBD group: primary diagnosis of at least one IBD. Direct expen-
ditures included medical expenditures (inpatient, outpatient, emergency department, 
and other medical services) and pharmacy expenditures. Indirect expenditures 
included expenditures related to absenteeism. Regression analysis was used to compare 
the mean number of annual absentee days, indirect expenditures associated with 
absences, direct expenditures (medical and pharmacy), and total expenditures between 
the two groups. RESULTS: The 2201 employees in the IBD group were matched to 
8,788 employees in the control group (mean age 42.2 years; mean risk score was 3.43; 
40% female; with 94% in managed care). Compared to the control group, the IBD 
group had slightly higher rate of absenteeism (9.1 vs. 9.0 days, slightly higher indirect 
expenditures ($1170 vs. $1129), higher direct expenditures ($8870 vs. $7500) includ-
ing medical expenditures ($6860 vs. $6096), and non anti-TNF pharmacy expendi-
tures ($1609 vs. $1404). The total expenditures (direct and indirect) were also higher 
for the IBD group ($9950 vs. $8630) compared to the control group. CONCLU-
SIONS: IBD is a debilitating disease that results in reduced productivity and time lost 
from work. Employees with IBD have a higher total health care expenditure burden. 
Appropriate management of IBD can reduce costs for employers and payers. Further 
analyses are needed to determine the impact of various treatment(s) on lost productiv-
ity and direct and indirect expenditures.
PSY14
COMPARISON OF ABSENTEEISM AND TOTAL HEALTH CARE 
EXPENDITURES FOR INFLAMMATORY BOWEL DISEASE PRE AND POST 
ANTI-TNF USE
Naim A1, Nair KV2, Van Den Bos J3, Draaghtel K3, Waters H4
1Centocor Ortho Biotech, Horsham, PA, USA, 2University of Colorado, Aurora, CO, USA, 
3Milliman, Inc, Denver, CO, USA, 4Centocor Ortho Biotech Services, LLC, Horsham, PA, 
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures pre- 
and post anti-TNF use among employees with inﬂammatory bowel disease (IBD). 
METHODS: A retrospective analysis was performed using the Thomson Reuters 
MarketScan® and the Health and Productivity Management databases between 
2000–2007. The study group consisted of individuals who had a primary diagnosis 
of at least one IBD and had at least one prescription for an anti-TNF agent (adalim-
umab, etanercept, or inﬂiximab) in the same calendar year. Direct expenditures 
included medical expenditures (inpatient, outpatient, emergency department, and 
other medical services) and pharmacy expenditures. Indirect expenditures included 
expenditures related to absenteeism. Regression analysis was used to compare the 
mean number of annual absence days and associated indirect expenditures, direct 
expenditures (medical and pharmacy), and total expenditures during the 12 months 
prior versus the 12 months following initiation of anti-TNF treatment. RESULTS: 
The study group had 87 members with a mean age of 41 years, 31% female, and 92% 
in a managed care plan. Following the use of anti-TNF agents, absenteeism was 39.8% 
lower (9.8 days vs.5.9 PMPY), and a similar decrease in indirect expenditures associ-
ated with absenteeism ($1,172 vs. $1,000) was observed. However, direct expendi-
tures were higher ($35,662 vs. $16,399) following the use of anti-TNF agents. This 
increase was primarily due to the cost of the anti-TNF agents themselves ($17,389), 
though annual medical expenditures were 13.2% higher ($15,810 vs. $13,968). Con-
sequently, total expenditures (direct and indirect) were also higher following anti-TNF 
use ($36,392 vs. $17,596). CONCLUSIONS: IBD results in reduced productivity and 
time lost from work. Members with at least one IBD who received anti-TNFs had 
lower absenteeism and lower indirect costs and higher direct costs. Employers and 
payers can develop appropriate management strategies like anti-TNF therapy to 
improve productivity and reduce indirect costs which may further offset total health 
care costs.
PSY15
STUDY OF FREQUENCY OF USE AND COSTS OF PATIENTS WITH 
CHRONIC PAIN AND NEUROPATHIC PAIN IN COLOMBIA FROM THIRD 
PARTY PAYERS PERSPECTIVE
Romero M1, Arango C2, Albanes J2
1Fundacion Salutia, Bogota, Colombia, 2Fundacion Salutia, bogota, Colombia
OBJECTIVES: Develop a cost study and frequency of care for patients with chronic 
pain or neuropathic pain by occupational disease or consequences of occupational 
accidents in Colombia between 2002 and 2008, from the perspective of third-party 
